Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 5Mouth Neoplasms 4Leukoplakia, Oral 3Erythroplasia 3Thyroid Nodule 2Thyroid Neoplasms 2Thyroid Diseases 2Insulin Resistance 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lymphoid Interstitial Pneumonia 1Leukoplakia 1Laryngeal Diseases 1Hyperplasia 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Squamous Cell Cancer 1Endometrial Neoplasms 1Diabetes Mellitus, Type 2 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Diseases 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 4spartalizumab 2tislelizumab 1obinutuzumab 1naptumomab estafenatox 1durvalumab 1Topotecan 1Rosiglitazone 1Nivolumab 1Metformin 1Gemcitabine 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Metformin × Head & Neck × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡